Drug class
Diphenylbutylpiperidine antipsychotic; dopamine D2 receptor antagonist (depot formulation)
Mechanism of action
Antagonises central dopamine D2 receptors, reducing dopaminergic signalling associated with psychotic symptoms. The depot formulation provides prolonged exposure following intramuscular administration.
General use cases
- Maintenance treatment of schizophrenia and other chronic psychotic disorders in countries where fluspirilene depot products remain authorised; not intended for rapid control of acute agitation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
